Table 1.

Diagnoses, disease duration, disease damage and disease activity scores in patients with vasculitis

Diagnosis	n (%)	Median disease duration in months (range)	VDI median score (range)	CDA median score (range)	BVAS v3 median score (range)
Wegener’s granulomatosis (with renal involvement)	104 (36.8)	36 (0–396)	2 (0–12)	4 (0–26)	1 (0–36)
Wegener’s granulomatosis (without renal involvement)	61 (21.6)	60 (1–300)	3 (0–8)	4 (0–21)	1 (0–39)
Microscopic polyangiitis	31 (11.0)	18.5 (0–252)	2 (0–7)	3 (0–12)	0 (0–25)
Churg–Strauss syndrome	24 (8.5)	38 (2–240)	3 (0–12)	3 (0–15)	2 (0–22)
Other vasculitis*	17 (6.0)	20.5 (0–228)	1 (0–9)	2 (0–16)	2 (0–17)
Henoch–Schönlein purpura	11 (3.9)	39 (2–360)	1 (0–5)	1 (0–11)	2 (0–15)
Mixed essential cryoglobulinaemia	11 (3.9)	49 (3–420)	2 (0–6)	4.5 (0–10)	6.5 (0–26)
Behçet’s disease	9 (3.2)	60 (7–480)	3 (0–7)	5 (1–8)	4 (0–18)
Takayasu’s arteritis	7 (2.5)	109 (36–264)	3 (0–4)	4 (0–7)	0 (0–4)
Isolated skin vasculitis	4 (1.4)	20.5 (4–78)	0 (0–4)	0.5 (0–9)	3.5 (2–5)
Polyarteritis nodosa (not HBV associated)	2 (0.7)	160 (114–206)	0.5 (0–1)	1 (0–2)	0.5 (0–1)
Systemic rheumatoid vasculitis	2 (0.7)	40 (32–48)	1.5 (1–2)	2 (2–2)	1 (1–1)

^*Other vasculitis comprised of: ANCA positive vasculitis not fitting any specific diagnosis (four patients); unspecified small vessel vasculitis (three patients); CNS vasculitis (three patients); not further specified (two patients); SLE vasculitis (one patient); giant cell arteritis (one patient); hypocomplementemic urticarial vasculitis (one patient), drug-induced vasculitis (one patient), Goodpasture’s syndrome (one patient).

ANCA, anti-neutrophil cytoplasmic antibody; BVAS v3, Birmingham Vasculitis Activity Score version 3; CDA, Combined Damage Assessment Index; CNS, central nervous system; HBV, hepatitis B virus; SLE, systemic lupus erythematosus; VDI, Vasculitis Damage Index.